Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think once people start to notice that SVACF this is a new Philip Frost pick, we might see this run back to higher levels.
same here. I'm a fan of frost plays especially when I can catch em at a decent bottom price. I payed Actinium too high but I think 19s are a good entry personally
Thanks for the word.
Have a green week.
I've been accumulating .16s - .18s. This is one of Frost's baby's. May take some time but I like it. Had a spin off a bit ago.
BooDog, this hit a scanner over the weekend.
Just checked it. Lo and behold, here you are. What's up?
http://stockcharts.com/h-sc/ui?s=SVACF&p=D&yr=0&mn=6&dy=0&id=p13664607182
Thanks.
Green Trades to you.
SVACF, VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/21/15 -- SciVac Therapeutics Inc. (TSX:VAC)(OTCQX:SVACF) announced today that its wholly-owned subsidiary SciVac Ltd. (the "Company") has received approval from the Israeli Ministry of Health to resume all standard manufacturing, including labeling and release of Sci-B-Vac™ to the market, following corrective actions to the automated labeling process and an inspection of the Company's facilities earlier this month.
Following an internal inspection which revealed that a number of packages of Sci-B-Vac™ hepatitis B vaccine contained a small number of damaged vials, the Company, after consulting with the Israeli Ministry of Health, recalled the batches of concern from the market as a precautionary measure. The Company has reported its findings to the Israeli Ministry of Health and to date there have been no reports of harm to any patients, nor have there been any reports or concerns with respect to Sci-B-Vac's™ efficacy or safety. The investigation carried out by the Company indicated that damage occurred in the labeling process, and since the recall was not based on the safety or efficacy of Sci-B-Vac™, the Company continued all other aspects of manufacturing without interruption during the brief time period following the recall.
SVACF, VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/21/15 -- SciVac Therapeutics Inc. (TSX:VAC)(OTCQX:SVACF) announced today that its wholly-owned subsidiary SciVac Ltd. (the "Company") has received approval from the Israeli Ministry of Health to resume all standard manufacturing, including labeling and release of Sci-B-Vac™ to the market, following corrective actions to the automated labeling process and an inspection of the Company's facilities earlier this month.
Following an internal inspection which revealed that a number of packages of Sci-B-Vac™ hepatitis B vaccine contained a small number of damaged vials, the Company, after consulting with the Israeli Ministry of Health, recalled the batches of concern from the market as a precautionary measure. The Company has reported its findings to the Israeli Ministry of Health and to date there have been no reports of harm to any patients, nor have there been any reports or concerns with respect to Sci-B-Vac's™ efficacy or safety. The investigation carried out by the Company indicated that damage occurred in the labeling process, and since the recall was not based on the safety or efficacy of Sci-B-Vac™, the Company continued all other aspects of manufacturing without interruption during the brief time period following the recall.
Sept looking to be the reversal month and hopefully some updates with the shareholder meeting on the 29th
little hidden gem here quite possibly. Shaping up nicely. seadog on twits mentioned this one to me about a month or so ago for the spin off divi. Still have some of both and I've added on this one on the dips. Going to keep this one tucked under my mattress for a while.
Good luck. I see Mick here now too. Hiya Mick, been a long time I think.
Cheers you guys!
LVNVF News: Report of Foreign Issuer (6-k) 07/30/2015 09:21:35 AM
LVNVF News: Report of Foreign Issuer (6-k) 07/20/2015 05:26:55 PM
LVNVF News: Report of Foreign Issuer (6-k) 07/17/2015 08:00:34 AM
LVNVF News: Report of Foreign Issuer (6-k) 07/07/2015 11:27:24 AM
LVNVF News: Report of Foreign Issuer (6-k)
SciVac Therapeutics (SVACF)
0.21 ? 0.0047 (2.29%)
Volume: 164,410 @ 3:53:19 PM ET
Bid Ask Day's Range
0.202 0.21 0.204963 - 0.21
SVACF Detailed Quote Wiki
hi my friend, thanx for invite. SVACF
SVACF, Frost Group LLC executive being nominated for BOD of SciVac. Assuming that will lead to the Frost Group buying stock in the company so they can have influence on the company right along side OPK and CLS Therapeutics. See today's news realease Page 8 for list of BOD and Nominee.
Company just released the Management information Circular for the Sept 29th shareholder meeting. Looks like Frost is putting is Frost Group, LLC Executive in for nomination to the Board of Directors of SVACF.
"Craig Edelstein. Craig Edelstein is an active venture investor and turnaround executive for Frost Group, LLC where he has worked since September 2008, utilizing his skills in finance, technology evaluation and business strategy. His current work for Frost Group, LLC and his parallel activity as an angel investor have resulted in a growing portfolio of investments and exits spanning internet/cybersecurity, cleantech, iosciences, and advanced materials. Mr. Edelstein also has broad operational experience in various industries including
software/hardware companies, public affairs/marketing activities, and hospitality management. In addition to his activities at Frost Group, LLC, Mr. Edelstein has been involved in his own family’s commercial real estate business, helping to execute a large multiparty land assembly deal and sale. He sits on the Board of Uriel Solar, Infinium Metals, and represents Frost Group, LLC on the Board of Morgan Solar. Mr. Edelstein received his MBA from MIT and was a Sloan Fellow, and received his MPA from The Harvard Kennedy School of Government. He also has a BA from the University of Pennsylvania.
-
http://content.stockpr.com/sec/0001493152-15-004151/0001493152-15-004151.pdf
SVACF, Size of Issuer (Assets): $100,000,001 to $500,000,000!!! According to Sedar.com SciVac has some good assets along with the Sci B Vac Vaccine. imo
http://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00004927
Recent article on Sci B Vac
http://www.tandfonline.com/doi/abs/10.1080/21645515.2015.1041687#/doi/abs/10.1080/21645515.2015.1041687
350k share bid support ay .26! good sign imo
Great article on SVACF, Dr. Frost and COCP
Go to the news under SVACF and pull up the story. It's a great story on Dr. Frost and the Hep space (both Hep C and Hep B). I think there is huge upside in both SVACF and COCP.
Kelly
Great article on SVACF and COCP and Dr. Frost
Go to the news under SVACF and pull up the story. It's a great story on Dr. Frost and the Hep space (both Hep C and Hep B). I think there is huge upside in both SVACF and COCP.
Kelly
Great way for me to double my position
Great way to start however
I agree with that, my guess they wanted to get that news out before dropping some good bombshell news on us
NOT a big deal at all, move on. Precautionary recall, limited to 2 markets and due to labeling issues. Nothing was wrong with the vaccine. Stock's performance today confirms the same.
BAD NEWS: RECALL OF HEP B PRODUCT
Oh boy....
KAE
SciVac Therapeutics Announces Precautionary Recall of Sci-B-Vac
When investing, it's best to do so with eyes open.
Kind regards,
Minding
===============
Marketwired SciVac Therapeutics Inc.
2 hours ago
????
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 30, 2015) - SciVac Therapeutics Inc. ("SciVac" or the "Company") (VAC.TO)(SVACF) announced today that, following discussions with the Israeli Ministry of Health (the "IMOH"), it is recalling from the market all Sci-B-Vac™ sold by the Company from January 1, 2012 to the present.
The Company is carrying out the recall solely as a precautionary measure, as, following inspection by SciVac, it was determined that certain unshipped packages of the Sci-B-Vac™ hepatitis B vaccine contained a small number of damaged vials. SciVac then reported its findings to the IMOH. There have been no reports of harm to any patients, nor have there been any reports with respect to Sci-B-Vac's™ efficacy or safety. Currently, the Company believes that an issue in the labeling process caused the damage, and the IMOH informed the Company that it may continue manufacturing Sci-B-Vac™ uninterrupted, so long as the Company uses an alternative labeling process until the issue can be appropriately remedied. The Company is diligently investigating the failure that resulted in the damaged vials.
The recall primarily affects the Israeli and Hong Kong markets.
About SciVac Therapeutics Inc.
SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company's flagship product, Sci-B-Vac™, is a recombinant 3rd generation hepatitis B vaccine. The Company also has in-licensed an early-stage enzyme-based product designated S-Graft, which is a recombinant human deoxyribonuclease I, a repurposed biological therapeutic intended for the prevention and treatment of graft-versus-host disease (GVHD). The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX), the Frankfurt Stock Exchange nor the OTCQX accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the expected effect of the product recall on the Company's business are forward-looking statements that involve various risks and uncertainties.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: market reaction to the recall, the effect of the recall on the use of Sci-B-Vac™ vaccine, the effect on the Company's operations of rectifying the issues that lead to the recall, litigation or regulatory action relating to the recall, the effect of the recall on the Company's actual financial results, general economic conditions and other factors detailed from time to time in the Company's periodic disclosure. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the Company's current expectations and it undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Contact:
SciVac Therapeutics Inc.
Curtis Lockshin
Chief Executive Officer
+972-8-948-0625
lockshin@scivactherapeutics.com
www.scivactherapeutics.com
That is the LVN 52 week low ?
Good man
Await buying pressure irrespective of price
Google finance has SVACF 52 week low at 0.17 . I'll be waiting close to that price(0.17+) to load up big. For now, I'll hold on buying until it gets there.
Time to buy imo
Wait for the pr
I guess if you are long it doesn't really matter. I'm still buying from time to time. I sure would like to know it's bottom so that I can buy a big block, and stop observing the price drop.
Down she goes, when she stops nobody knows
Job Opening could use some help, Moderators, Wanted.... Iam not so good at knowing how to Make the Home Page....Better...Hmmm, Any one who hsa time to help let me know.....
Like to keep it simple, no flashy blue lights and such.....
Thank you.....I will try to make it better, SVACF is not a pump & dump stock.....So like to keep it that way.......
posted on the old LVNVF yahoo mb but here is my thoughts on SCIVAC:
SCIVAC connections: CLS therapeutics and Xenetic Biosciences
CLS therapeutics recently acquired a large number of shares of scivac. The agreement allows scivac to develop and commercialize a bunch of their patents and pre-clinical research. They have a great IP portfolio and looks promising. In addition, Russian OJSC Pharmsynthez and their management (including Dmitry Genkin- who also was involved with FDS pharma) owns a large part of CLS therapeutics as well as Xenetic Biosciences (XBIO). XBIO recently came out with positive data on their long acting EPO drug for CKD and other diseases. They also have a long acting oxyntomodulin (for diabetes).... Sound familiar? Thats because OPKO is working on drugs for long acting oxyntomodulin (acquired by OPKO during Prolor deal). Also OPKO is working on CKD drugs
OH THE CIRCLE OF CONNECTIONS.... check out these companies... they will all end up being acquired by OPKO within time... FROST is building an empire, glad i can be a part of it.
Long road yet
Sci vac commercialisation in the us in 2018
Clinical trials q2 2016
Pg 26 form 20 F
The issue of New Levon Shares under the SciVac Arrangement and their subsequent sale may cause the market price of New Levon Shares to decline.
As of the date of this Annual Report on Form 20-F, 231,564,423 Levon shares were outstanding and an aggregate of 21,597,500 Levon shares were subject to outstanding Levon options. Up to 801,145,325 New Levon Shares may be issued or issuable in connection with the SciVac Arrangement. The issue of these New Levon Shares and their sale and the sale of additional New Levon Shares that may become eligible for sale in the public market from time to time could depress the market price for Levon Shares.
The longer the wait until the first pr the lower we will go, definitely under 30 cents imo with quick retrace to 43+ after meaty pr update.
J85, just wanted to let you know Fidelity just made the transition from Levon to SVACF. Thank you for information. Peace be with you.
I will continue to buy as it drops lower. I'm far from the amount of shares I want to own. COCP has 693.14 Million shares, and an OS of 329.68 Million and trading at $1.03, which I never thought would happen so soon. I will do the same buying for SVACF as I did for COCP. Out of curiosity, how low do you think it will go?
Wait for a bit
It will go lower
I am in. After everything has cleared up, SVACF should be heading to $1.00+. Best time to buy is now. IMO
J85, thank you.
you should've bought on the last day which was monday, transition already took place.
Question for all!
I bought some shares of LEVON on Monday. Maybe I misunderstood but I was expecting it to be converted to the new stock SVACF. Being ignorant did I miss something?
Thank you kindly
Skinman
Thanks, HOPE the best for All, Pretty sure this is a winner....
Reply from Levon IR on new mining shares to be issued. "Three business days from Thursday give it a day here for them to be put
into your account by Valiant Trust or phone them at 1-866-313-1872"
Looks like its go time
What a disaster
Going to be an interesting day, either way the m
Levon Resources Ltd., LVNVF, changed to SciVac Therapeutics Inc., SVACF:
http://otce.finra.org/DLSymbolNameChanges
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
243
|
Created
|
06/04/15
|
Type
|
Free
|
Moderators |
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
Today, Frost accomplished his goal, as SciVac has been officially acquired by Levon Resources (OTCMKTS:LVNVF), with 68.4% of the new company going to the former private SciVac shareholders and 31.6% going to former Levon shareholders. Since Opko already has a 45% stake in SciVac, that brings its total take in SciVac to 30.8%.
The deal still has to be voted on by current Levon shareholders in April, but is expected to pass.
Opko has had some success taking stakes in biotech companies so far this year. Its recent 8% stake in Cocrystal Pharma (OTCBB:COCP) has jumped 100% since February. Cocrystal is its second largest investment behind private Russian biotech Pharmsynthez.
SciVac's Hepatitis B Vaccine
SciVac is the developer of a third generation hepatitis B vaccine (HBV) called Sci-B-Vac . It is approved in several countries including SciVac's home country of Israel, where it is administered to hundreds of thousands of newborns each year. While first generation HBV vaccines are mostly effective, their effectiveness is still only 90%. In a clinical trial of over 5,000 people, Sci-B-Vac was shown to have an effectiveness of greater than 98% with higher immunogenicity, or immune response in terms of antibodies produced.
The difference between Sci-B-Vac and the current standard-of-care HBV vaccine is that Sci-B-Vac is derived from mammalian cells instead of yeast cells, and carries on it the three main HBV surface antigens instead of just one. It is believed that the 10% of people who do not respond to first generation HBV vaccines are infected with mutant versions of HBV that escape the single antigen vaccine. It is much harder for HBV to mutate all three surface antigens simultaneously to escape Sci-B-Vac.
Despite vaccines available, HBV is still a huge pandemic. According to the World Health Organization, one third of the world's population is infected with HBV, with up to 400M people suffering chronic infections leading to chronic liver disease. 250M of those people are in the Asia-Pacific region alone.
SciVac's next regulatory goal is approval in the United States, where 12M people are infected every year despite the current first generation vaccine available. What regulatory hurdles have to be overcome remains to be seen, given that Sci-B-Vac is already clinically tested and approved in several countries. SciVac will be aiming at the immunocompromised as well as end stage renal disease and HIV patients, as these are patient populations who have special difficulties responding to current HBV vaccines.
Context of Frost's Latest Move Hints at Possible Future Moves
Dr. Frost's latest move comes in the context of several other interesting stock movements that may tip off future deals in the making. In October last year, only one month after Globes reported Frost's interest in taking SciVac public, Levon acquired 35M shares, or 10% of Pershing Gold Corporation, another one of Frost's pet projects of which he has a 15% stake translating to 53.7M shares. Those 35M shares of PGLC will be moving to new entity Spinco, so speculators looking out for the next Frost-related deal should keep an eye on a possible merger between Spinco and Pershing. A similar deal was inked bewteen Pershing and Continental Resources Group in February 2013 where the latter was acquired by Pershing. Continental had a substantial stake in Pershing at the time.
Cocrystal, which is fairly similar to SciVac in that it is focusing on molecularly tailored vaccines, primarily hepatitis C. Cocrystal is also 22% owned by Frost through his investment trust as well as an 8% stake through Opko. Cocrystal has skyrocketed over 100% since February but lacking any obvious catalyst for doing so. Another possible move to watch then is for a deal between Levon, now SciVac, and Cocrystal, which itself was once BioZone, also an Opko investment that was merged into Cocrystal.
With Frost's myriad of moves and deals over the last few years things can get admittedly confusing and make your head spin. The structure of these mergers, however, repeatedly seems to start with Opko at the base and then moves out from there. Opko itself has been on a nearly 100% tear since December. As for Cocrystal's recent 100% move, it may have investors scratching their heads but connecting the dots here could point to the beginning stages of a Frost deal at some point between Cocrystal and SciVac as both specialize in hepatitis vaccines, as well as one between Spinco and Pershing.
Call it equity consolidation with synergies in mind, it certainly is a fascinating chess game.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |